LOG IN
SIGN UP
MARKET
RDUS
RDUS
Radius Health
NASDAQ
Real-time Quotes | Nasdaq Last Sale
6.12
+0.02
+0.33%
After Hours: 6.12 0 0.00% 16:11 05/27 EDT
OPEN
6.09
PREV CLOSE
6.10
HIGH
6.15
LOW
5.67
VOLUME
776.63K
TURNOVER
0
52 WEEK HIGH
23.00
52 WEEK LOW
4.970
MARKET CAP
291.13M
P/E (TTM)
-3.9870
1D
5D
1M
3M
1Y
5Y
Goldman Trims Radius Health's Price Target to $8 From $9, Neutral Rating Reiterated
MT Newswires · 3d ago
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Benzinga · 4d ago
SVB Securities Initiates Radius Health at Market Perform With $7 Price Target
MT Newswires · 4d ago
Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug
Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.
Zacks · 05/20 16:54
Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer
The Menarini Group and Radius Health Inc's (NASDAQ: RDUS) data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology.
Benzinga · 05/20 13:46
Do Options Traders Know Something About Radius Health (RDUS) Stock We Don't?
Investors need to pay close attention to Radius Health (RDUS) stock based on the movements in the options market lately.
Zacks · 05/20 12:52
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") (NASDAQ: RDUS) (collectively, the "Companies") today announced that data from the pivotal phase 3 EMERALD clinical trial (NCT03778931) evaluating elacestrant as a monotherapy vs. standard o...
PR Newswire · 05/20 08:17
Radius Health, Menarini Group Says Phase 3 Trial of Breast Cancer Drug Candidate Elacestrant Meets Primary Endpoint
MT Newswires · 05/20 05:14
No Data
Learn about the latest financial forecast of RDUS. Analyze the recent business situations of Radius Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 7 analysts
Hold
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
0.00%Buy
71.43%Hold
28.57%Under-perform
0.00%Sell
Analyst Price Target
The average RDUS stock price target is 8.67 with a high estimate of 10.00 and a low estimate of 7.00.
Current 6.12
EPS
Actual
Estimate
-0.36-0.26-0.15-0.04
Institutional Holdings
Institutions: 210
Institutional Holdings: 65.51M
% Owned: 137.72%
Shares Outstanding: 47.57M
TypeInstitutionsShares
Increased
47
6.11M
New
21
2.78M
Decreased
42
4.84M
Sold Out
19
1.58M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Owen Hughes
President/Chief Executive Officer/Director
G. Kelly Martin
Chief Financial Officer/Vice President/Treasurer
Mike Conley
Senior Vice President
Salvador Grausso
Senior Vice President
Chhaya Shah
General Counsel
Kim Clarke
Independent Director
Willard Dere
Independent Director
Catherine Friedman
Independent Director
Jean-Pierre Garnier
Independent Director
Sean Murphy
Independent Director
A. Machelle Sanders
Independent Director
Andrew Von Eschenbach
No Data
No Data
About RDUS
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).
Webull offers kinds of Radius Health Inc stock information, including NASDAQ:RDUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDUS stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading RDUS stock methods without spending real money on the virtual paper trading platform.